4.7 Review

Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers

Journal

BRITISH JOURNAL OF PHARMACOLOGY
Volume 164, Issue 1, Pages 37-47

Publisher

WILEY
DOI: 10.1111/j.1476-5381.2011.01402.x

Keywords

memory; angiotensin IV; GLUT4; peptidomimetic; vasopressin; oxytocinase; glucose; drug development

Funding

  1. National Health and Medical Research Council of Australia (NHMRC) [520695, 502602]
  2. Neurosciences Victoria
  3. Alzheimer's Drug Discovery Foundation USA

Ask authors/readers for more resources

Two structurally distinct peptides, angiotensin IV and LVV-haemorphin 7, both competitive high-affinity inhibitors of insulin-regulated aminopeptidase (IRAP), were found to enhance aversion-associated and spatial memory in normal rats and to improve performance in a number of memory tasks in rat deficits models. These findings provide compelling support for the development of specific, high-affinity inhibitors of the enzyme as new cognitive enhancing agents. Different classes of IRAP inhibitors have been developed including peptidomimetics and small molecular weight compounds identified through in silico screening with a homology model of the catalytic domain of IRAP. The proof of principal that inhibition of IRAP activity results in facilitation of memory has been obtained by the demonstration that the small-molecule IRAP inhibitors also exhibit memory-enhancing properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available